Susceptibility loci associated with prostate cancer progression and mortality. - Wikidata - awgldk - TriplyDB

Susceptibility loci associated with prostate cancer progression and mortality.

Susceptibility loci associated with prostate cancer progression and mortality.

http://www.wikidata.org/entity/Q41785590

about

Current status of biomarkers for prostate cancer The genetics of cancer risk Genetic variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF genes are prognostic markers of prostate cancer-specific mortality.An Integrative Genomics Approach for Associating Genome-Wide Association Studies Information With Localized and Metastatic Prostate Cancer Phenotypes Genetic variation in DNA repair pathways and risk of non-Hodgkin's lymphoma.The prostate cancer susceptibility variant rs2735839 near KLK3 gene is associated with aggressive prostate cancer and can stratify gleason score 7 patients Melanoma risk loci as determinants of melanoma recurrence and survival Association of GWAS-identified lung cancer susceptibility loci with survival length in patients with small-cell lung cancer treated with platinum-based chemotherapy Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels Prognostic relevance of urinary bladder cancer susceptibility loci.Y chromosome haplogroups and prostate cancer in populations of European and Ashkenazi Jewish ancestry Associations of prostate cancer risk variants with disease aggressiveness: results of the NCI-SPORE Genetics Working Group analysis of 18,343 cases.Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50.An analysis of the association between prostate cancer risk loci, PSA levels, disease aggressiveness and disease-specific mortality Variation in IL10 and other genes involved in the immune response and in oxidation and prostate cancer recurrence Characterization of the Glycosylation Site of Human PSA Prompted by Missense Mutation using LC-MS/MS.Imaging and Markers as Novel Diagnostic Tools in Detecting Insignificant Prostate Cancer: A Critical Overview Utility of genome-wide association study findings: prostate cancer as a translational research paradigm.Germline determinants of clinical outcome of cutaneous melanoma.Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality.Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer.Genetic variants within endothelial nitric oxide synthase gene and prostate cancer: a meta-analysis.Prostate cancer (PCa) risk variants and risk of fatal PCa in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium.Molecular genetics of prostate cancer: emerging appreciation of genetic complexity.Prostate cancer: germline prediction for a commonly variable malignancy.The complexity of prostate cancer: genomic alterations and heterogeneity.Integration of genomics in cancer care.The genetic epidemiology of prostate cancer and its clinical implications.Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer.Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer.Prostate Cancer Genetics: A Review.Prostate cancer risk variants are not associated with disease progression.Genetic variants in the TEP1 gene are associated with prostate cancer risk and recurrence.The identification of trans-associations between prostate cancer GWAS SNPs and RNA expression differences in tumor-adjacent stroma.Assessment of association between common variants at 17q12 and prostate cancer risk-evidence from Serbian population and meta--analysis.Assessment of possible association between rs3787016 and prostate cancer risk in Serbian population.Association between KLK3 rs2735839 G/A polymorphism and serum PSA levels in Japanese men.Clinical uncertainty of prostate cancer genetic risk panels.Genetic predisposition to early recurrence in clinically localized prostate cancer.Impact of Occupational Exposures and Genetic Polymorphisms on Recurrence and Progression of Non-Muscle-Invasive Bladder Cancer

P2860

Q24600574-B153EA78-B0C3-4733-900F-C900BF930027 Q27013910-340E6CB6-62A4-4161-9A3D-97647C2D760C Q30504100-9E446FB6-106E-4BD7-808C-EFCF5B8CA929 Q33565740-D23DE265-173A-42DB-8545-7DB6D6BE9D23 Q33882519-3DD9C05E-DFB6-4E85-B4AA-178C674344B0 Q34290163-3AA7292A-074F-49C2-B656-408EA3F0A857 Q34493237-49CAD59D-686A-4793-8B2D-69B0519A8340 Q34557311-77EAF774-C439-4D19-A9DD-D30EF068D864 Q35020463-4446B5C1-8550-4B65-B56A-A8DC30E801F0 Q35106772-525FB8CF-859A-4010-92BE-317D2E59A929 Q36028638-C99A8B46-1783-4E95-AD2C-51356DC1724E Q36100579-53400954-5857-4C78-A69B-7BA93B883E0C Q36142693-26753BBB-CCB6-46DC-A8EA-69C302CEC90F Q36286694-158A4D91-D3A7-4E91-9395-F98B669D8EB8 Q36306209-43D9B68F-F34F-40A6-A8D2-91AF236B65FB Q36900678-4534736A-ECEF-4E05-84B1-8340FFE9FB1E Q36979944-63F61520-95C6-4C0D-9E4E-BE2FD5DD8E52 Q37122541-D99E72C7-4A43-43E8-85E3-32ACEDBA2EE5 Q37258423-E21BE031-211F-431A-9AA3-00E64E44FA82 Q37262639-5CC2CCFD-CD21-4472-936D-ADC7704BD2A7 Q37622580-4D921059-6AA2-4577-9D95-E9379B46B3AA Q37700582-DCA8B751-F684-4454-98DC-1D7E463EE2B6 Q37735483-C16BA7A8-FC4B-4D28-ADA1-F62BB7144F48 Q37972706-193A1E12-265C-4659-91E2-7D8D725BA40C Q38043095-AF65E732-3E1A-43BA-9B19-DF2C660961B1 Q38058243-B61CB383-8F1E-4003-86E9-BA17CD31B5D9 Q38072148-2862CB4F-59DA-4273-98BE-93D676882A1B Q38168060-E67FC23F-4B19-4ADB-86A5-6F2C783F0D15 Q38854599-E92F48F3-71CB-48B9-B37B-0FD9EAF3FBDE Q38855675-B40AA3EC-3DA2-4B5B-9E40-5A802A6429DD Q38967495-50950719-2306-4AB7-A981-C7FECFE71EC8 Q39757112-0CDF64AA-DBA7-4351-B6F7-32E771F8460D Q40665254-633870D3-D410-48C7-840F-6633CA8E556C Q42102286-47D176EF-B729-4A2E-A33A-4F0400CC2560 Q42252484-A0B0F2CD-A25D-498B-BDDE-1A66BE2A89BC Q42393115-26B05C15-8311-40CE-9EFC-65891C50A146 Q43633268-F9A422CC-CB84-4520-8B77-E2B2749E40BF Q45920438-7469E184-6229-4BFF-A585-6B8C4788BD72 Q46304406-D61C63E9-BFFA-4610-9D8F-E5283C1F7209 Q58463132-6E8EE224-7398-4645-8104-FD40EF7BFC4D

P2860

Susceptibility loci associated with prostate cancer progression and mortality.

http://www.wikidata.org/entity/Q41785590

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Susceptibility loci associated with prostate cancer progression and mortality.

@en

type

label

Susceptibility loci associated with prostate cancer progression and mortality.

@en

prefLabel

Susceptibility loci associated with prostate cancer progression and mortality.

@en

P1433

Q41785590-3AF8524E-E0DD-4623-AA0A-1BD65ED683C2

P1476

Q41785590-6E204898-C426-4289-9484-9A2A82764241

P2093

Q41785590-04372E1D-538F-43D5-A2BD-6AF2D3BF6569

Q41785590-1CB0351A-22CB-4B5B-837F-5F5013883799

Q41785590-217D8EBA-0FCD-4EC7-A467-0FD6228B150E

Q41785590-5E4989BB-15CF-402C-BAA3-9023B0E1F34D

Q41785590-6548CD16-A0D4-4CDE-8DB4-90FDEB528892

Q41785590-6C53D6DF-CFD9-4718-9623-98E20FD34A4A

Q41785590-97FD3B89-012D-4B61-BEE2-F5F379BE9DB1

Q41785590-A280E864-304B-4E5F-B528-B0EBC405E1E0

Q41785590-C6F24B6D-265C-4724-B54C-A6501B6378E1

Q41785590-EA58EFA0-CF6F-49E4-924E-797FF8C15761

P2860

Q41785590-02A4D3C4-4C0C-4DD7-8019-D39F253B4D0A

Q41785590-05E9E925-4764-4889-B45A-48BC9ACE5195

Q41785590-07FDF631-8C6E-4418-8BEB-585CD748CA7C

Q41785590-0C57FA0A-4155-451C-8B07-071B6227ABFE

Q41785590-0F8377FB-02DB-4D38-9C36-486801062385

Q41785590-11085E65-D8D1-44E2-AC25-B1B3290E6F5F

Q41785590-11EA0FB4-7712-4219-80BD-9369168E0C2C

Q41785590-13C97D4E-138C-45B4-9171-E1A2BB93CAB3

Q41785590-174DD72A-B3A9-4BFC-9E81-1605366F6209

Q41785590-19F3316E-5B86-4E68-A7F7-DBA84D1DDC2B

P304

Q41785590-2297BA02-646B-421E-BFEA-B4CC189BDB4C

P31

Q41785590-518D2E25-767E-401D-B005-7DC7797E5873

P356

Q41785590-3886572E-CD92-4482-8125-9E7E3D9578B3

P407

Q41785590-62DCB055-4BB1-40D0-BA28-BAA654AE3842

P433

Q41785590-93F39AC7-8458-426F-964A-C7E6C709AE02

P478

Q41785590-5FAB12C2-12F7-43A6-8988-8D325C7966F6

P50

Q41785590-0B7E5560-91D2-4FF5-964B-887C702DA6CD

Q41785590-0DDDE863-379C-445D-84B7-190A19DDA45F

Q41785590-3CE5F8DE-B920-4CC5-B8C3-87D4566614F0

Q41785590-618BFF13-6EED-4A10-9B8D-4154C6356934

Q41785590-AA44AA72-6AFF-471D-B737-FBE43DB37F8D

Q41785590-FD2D6EAC-9332-4279-9F95-CC3467D08EF1

P577

Q41785590-1ED84840-A18B-442A-A3E7-7B5B4C36AD92

P5875

Q41785590-34F50E07-2C95-4A27-A429-1192FECB873F

P698

Q41785590-8311999F-8086-4A2D-A66D-51A375AB7111

P921

Q41785590-68C7E7D3-6CE5-45C7-8BC2-03F8A85276C8

P932

Q41785590-1302C23F-4B85-41CE-AEC5-9C4F6BFD1DF0

P356

1078-0432.CCR-10-0028

P1433

Clinical Cancer Research

P1476

Susceptibility loci associated with prostate cancer progression and mortality.

@en

P2093

Ana Dutra-Clarke

http://www.w3.org/2001/XMLSchema#string

Angel M Cronin

http://www.w3.org/2001/XMLSchema#string

Christer Halldén

http://www.w3.org/2001/XMLSchema#string

Howard I Scher

http://www.w3.org/2001/XMLSchema#string

James A Eastham

http://www.w3.org/2001/XMLSchema#string

Jasmine Bhatia

http://www.w3.org/2001/XMLSchema#string

Mia M Gaudet

http://www.w3.org/2001/XMLSchema#string

Peter T Scardino

http://www.w3.org/2001/XMLSchema#string

Robert J Klein

http://www.w3.org/2001/XMLSchema#string

Samson Fine

http://www.w3.org/2001/XMLSchema#string

P2860

Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors

Multiple newly identified loci associated with prostate cancer susceptibility

Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer

Multiple loci identified in a genome-wide association study of prostate cancer

Genome-wide association study of prostate cancer identifies a second risk locus at 8q24

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium.

Clinical utility of five genetic variants for predicting prostate cancer risk and mortality.

Evaluation of 8q24 and 17q risk loci and prostate cancer mortality.

Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916

P304

2819-2832

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-10-0028

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Andrew J Vickers

David J Gallagher

Tomas Kirchhoff

P577

2010-05-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44590202

http://www.w3.org/2001/XMLSchema#string

P698

20460480

http://www.w3.org/2001/XMLSchema#string

P921

susceptibility locus

P932

3732009

http://www.w3.org/2001/XMLSchema#string